| Literature DB >> 31907406 |
Malin Parmar1,2, Shane Grealish3,4, Claire Henchcliffe5.
Abstract
Cell-replacement therapies have long been an attractive prospect for treating Parkinson disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with Parkinson disease have been variable, in part owing to the limitations of fetal tissue as a cell source, relating to its availability and the lack of possibility for standardization and to variation in methods. Advances in developmental and stem cell biology have allowed the development of cell-replacement therapies that comprise dopamine neurons derived from human pluripotent stem cells, which have several advantages over fetal cell-derived therapies. In this Review, we critically assess the potential trajectory of this line of translational and clinical research and address its possibilities and current limitations and the broader range of Parkinson disease features that dopamine cell replacement based on generating neurons from human pluripotent stem cells could effectively treat in the future.Entities:
Mesh：
Year: 2020 PMID： 31907406 DOI： 10.1038/s41583-019-0257-7
Source DB: PubMed Journal: Nat Rev Neurosci ISSN： 1471-003X Impact factor: 34.870